Single session of high-intensity focused ultrasound for localized prostate cancer: treatment outcomes and potential effect as a primary therapy

Kazumasa Komura, Teruo Inamoto, Tomoaki Takai, Taizo Uchimoto, Kenkichi Saito, Naoki Tanda, Junko Kono, Koichiro Minami, Hirohumi Uehara, Yutaka Fujisue, Kiyoshi Takahara, Hajime Hirano, Hayahito Nomi, Toshikazu Watsuji, Satoshi Kiyama, Haruhito Azuma

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Purpose: To investigate the treatment outcomes of a single-session high-intensity focused ultrasound (HIFU) using the Sonablate® for patients with localized prostate cancer.

Methods: Biochemical failure was defined according to the Stuttgart definition [a rise of 1.2 ng/ml or more above the nadir prostate-specific antigen (PSA)] and the Phoenix definition (a rise of 2 ng/ml or more above the nadir PSA). Disease-free survival rate was defined using the Phoenix criteria and positive follow-up biopsy.

Results: A total of 171 patients were identified. Fifty-two (30.4 %) patients were identified to be with D’Amico low risk, 47 (27.5 %) with intermediate risk, and 72 (42.1 %) with high risk. In the median follow-up time of 43 months, there was 44 (25.7 %) and 36 (21.1 %) patients experienced biochemical failure for Stuttgart and Phoenix definition with mean (±SD) time to failure of 17.8 ± 2.1 and 19.4 ± 2.3 months, respectively. A total of 44 (25.7 %) patients were diagnosed as disease failure. Cox multivariate analysis revealed PSA nadir level (PSA cutoff = 0.2 ng/ml; HR = 9.472, 95 % CI 4.527–19.820, p < 0.001) and D’amico risk groups [HR = 3.132 (95 % CI 1.251–6.389), p = 0.033] were the predictor for failure in single-session HIFU.

Conclusions: Single-session HIFU treatment using the Sonablate® seems to be potentially curative approach. When treated carefully with neoadjuvant hormonal therapy or preoperative transurethral resection of the prostate, higher-risk disease might be able to choose this minimally invasive procedure as primary therapy.

Original languageEnglish
Pages (from-to)1339-1345
Number of pages7
JournalWorld Journal of Urology
Volume32
Issue number5
DOIs
Publication statusPublished - 01-01-2013

Fingerprint

Prostatic Neoplasms
Prostate-Specific Antigen
Therapeutics
Transurethral Resection of Prostate
Neoadjuvant Therapy
Disease-Free Survival
Multivariate Analysis
Survival Rate
Biopsy

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Komura, Kazumasa ; Inamoto, Teruo ; Takai, Tomoaki ; Uchimoto, Taizo ; Saito, Kenkichi ; Tanda, Naoki ; Kono, Junko ; Minami, Koichiro ; Uehara, Hirohumi ; Fujisue, Yutaka ; Takahara, Kiyoshi ; Hirano, Hajime ; Nomi, Hayahito ; Watsuji, Toshikazu ; Kiyama, Satoshi ; Azuma, Haruhito. / Single session of high-intensity focused ultrasound for localized prostate cancer : treatment outcomes and potential effect as a primary therapy. In: World Journal of Urology. 2013 ; Vol. 32, No. 5. pp. 1339-1345.
@article{02f4b3e3a8c848e3a6dc3af36610b6bb,
title = "Single session of high-intensity focused ultrasound for localized prostate cancer: treatment outcomes and potential effect as a primary therapy",
abstract = "Purpose: To investigate the treatment outcomes of a single-session high-intensity focused ultrasound (HIFU) using the Sonablate{\circledR} for patients with localized prostate cancer.Methods: Biochemical failure was defined according to the Stuttgart definition [a rise of 1.2 ng/ml or more above the nadir prostate-specific antigen (PSA)] and the Phoenix definition (a rise of 2 ng/ml or more above the nadir PSA). Disease-free survival rate was defined using the Phoenix criteria and positive follow-up biopsy.Results: A total of 171 patients were identified. Fifty-two (30.4 {\%}) patients were identified to be with D’Amico low risk, 47 (27.5 {\%}) with intermediate risk, and 72 (42.1 {\%}) with high risk. In the median follow-up time of 43 months, there was 44 (25.7 {\%}) and 36 (21.1 {\%}) patients experienced biochemical failure for Stuttgart and Phoenix definition with mean (±SD) time to failure of 17.8 ± 2.1 and 19.4 ± 2.3 months, respectively. A total of 44 (25.7 {\%}) patients were diagnosed as disease failure. Cox multivariate analysis revealed PSA nadir level (PSA cutoff = 0.2 ng/ml; HR = 9.472, 95 {\%} CI 4.527–19.820, p < 0.001) and D’amico risk groups [HR = 3.132 (95 {\%} CI 1.251–6.389), p = 0.033] were the predictor for failure in single-session HIFU.Conclusions: Single-session HIFU treatment using the Sonablate{\circledR} seems to be potentially curative approach. When treated carefully with neoadjuvant hormonal therapy or preoperative transurethral resection of the prostate, higher-risk disease might be able to choose this minimally invasive procedure as primary therapy.",
author = "Kazumasa Komura and Teruo Inamoto and Tomoaki Takai and Taizo Uchimoto and Kenkichi Saito and Naoki Tanda and Junko Kono and Koichiro Minami and Hirohumi Uehara and Yutaka Fujisue and Kiyoshi Takahara and Hajime Hirano and Hayahito Nomi and Toshikazu Watsuji and Satoshi Kiyama and Haruhito Azuma",
year = "2013",
month = "1",
day = "1",
doi = "10.1007/s00345-013-1215-z",
language = "English",
volume = "32",
pages = "1339--1345",
journal = "World Journal of Urology",
issn = "0724-4983",
publisher = "Springer Verlag",
number = "5",

}

Komura, K, Inamoto, T, Takai, T, Uchimoto, T, Saito, K, Tanda, N, Kono, J, Minami, K, Uehara, H, Fujisue, Y, Takahara, K, Hirano, H, Nomi, H, Watsuji, T, Kiyama, S & Azuma, H 2013, 'Single session of high-intensity focused ultrasound for localized prostate cancer: treatment outcomes and potential effect as a primary therapy', World Journal of Urology, vol. 32, no. 5, pp. 1339-1345. https://doi.org/10.1007/s00345-013-1215-z

Single session of high-intensity focused ultrasound for localized prostate cancer : treatment outcomes and potential effect as a primary therapy. / Komura, Kazumasa; Inamoto, Teruo; Takai, Tomoaki; Uchimoto, Taizo; Saito, Kenkichi; Tanda, Naoki; Kono, Junko; Minami, Koichiro; Uehara, Hirohumi; Fujisue, Yutaka; Takahara, Kiyoshi; Hirano, Hajime; Nomi, Hayahito; Watsuji, Toshikazu; Kiyama, Satoshi; Azuma, Haruhito.

In: World Journal of Urology, Vol. 32, No. 5, 01.01.2013, p. 1339-1345.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Single session of high-intensity focused ultrasound for localized prostate cancer

T2 - treatment outcomes and potential effect as a primary therapy

AU - Komura, Kazumasa

AU - Inamoto, Teruo

AU - Takai, Tomoaki

AU - Uchimoto, Taizo

AU - Saito, Kenkichi

AU - Tanda, Naoki

AU - Kono, Junko

AU - Minami, Koichiro

AU - Uehara, Hirohumi

AU - Fujisue, Yutaka

AU - Takahara, Kiyoshi

AU - Hirano, Hajime

AU - Nomi, Hayahito

AU - Watsuji, Toshikazu

AU - Kiyama, Satoshi

AU - Azuma, Haruhito

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Purpose: To investigate the treatment outcomes of a single-session high-intensity focused ultrasound (HIFU) using the Sonablate® for patients with localized prostate cancer.Methods: Biochemical failure was defined according to the Stuttgart definition [a rise of 1.2 ng/ml or more above the nadir prostate-specific antigen (PSA)] and the Phoenix definition (a rise of 2 ng/ml or more above the nadir PSA). Disease-free survival rate was defined using the Phoenix criteria and positive follow-up biopsy.Results: A total of 171 patients were identified. Fifty-two (30.4 %) patients were identified to be with D’Amico low risk, 47 (27.5 %) with intermediate risk, and 72 (42.1 %) with high risk. In the median follow-up time of 43 months, there was 44 (25.7 %) and 36 (21.1 %) patients experienced biochemical failure for Stuttgart and Phoenix definition with mean (±SD) time to failure of 17.8 ± 2.1 and 19.4 ± 2.3 months, respectively. A total of 44 (25.7 %) patients were diagnosed as disease failure. Cox multivariate analysis revealed PSA nadir level (PSA cutoff = 0.2 ng/ml; HR = 9.472, 95 % CI 4.527–19.820, p < 0.001) and D’amico risk groups [HR = 3.132 (95 % CI 1.251–6.389), p = 0.033] were the predictor for failure in single-session HIFU.Conclusions: Single-session HIFU treatment using the Sonablate® seems to be potentially curative approach. When treated carefully with neoadjuvant hormonal therapy or preoperative transurethral resection of the prostate, higher-risk disease might be able to choose this minimally invasive procedure as primary therapy.

AB - Purpose: To investigate the treatment outcomes of a single-session high-intensity focused ultrasound (HIFU) using the Sonablate® for patients with localized prostate cancer.Methods: Biochemical failure was defined according to the Stuttgart definition [a rise of 1.2 ng/ml or more above the nadir prostate-specific antigen (PSA)] and the Phoenix definition (a rise of 2 ng/ml or more above the nadir PSA). Disease-free survival rate was defined using the Phoenix criteria and positive follow-up biopsy.Results: A total of 171 patients were identified. Fifty-two (30.4 %) patients were identified to be with D’Amico low risk, 47 (27.5 %) with intermediate risk, and 72 (42.1 %) with high risk. In the median follow-up time of 43 months, there was 44 (25.7 %) and 36 (21.1 %) patients experienced biochemical failure for Stuttgart and Phoenix definition with mean (±SD) time to failure of 17.8 ± 2.1 and 19.4 ± 2.3 months, respectively. A total of 44 (25.7 %) patients were diagnosed as disease failure. Cox multivariate analysis revealed PSA nadir level (PSA cutoff = 0.2 ng/ml; HR = 9.472, 95 % CI 4.527–19.820, p < 0.001) and D’amico risk groups [HR = 3.132 (95 % CI 1.251–6.389), p = 0.033] were the predictor for failure in single-session HIFU.Conclusions: Single-session HIFU treatment using the Sonablate® seems to be potentially curative approach. When treated carefully with neoadjuvant hormonal therapy or preoperative transurethral resection of the prostate, higher-risk disease might be able to choose this minimally invasive procedure as primary therapy.

UR - http://www.scopus.com/inward/record.url?scp=84887960475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887960475&partnerID=8YFLogxK

U2 - 10.1007/s00345-013-1215-z

DO - 10.1007/s00345-013-1215-z

M3 - Article

C2 - 24270943

AN - SCOPUS:84887960475

VL - 32

SP - 1339

EP - 1345

JO - World Journal of Urology

JF - World Journal of Urology

SN - 0724-4983

IS - 5

ER -